(XERS) Xeris Pharmaceuticals - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.063m USD | Total Return: 38% in 12m
Avg Turnover: 8.73M
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
P/E ratio 88.0
Share dilution 16.5% YoY
Altman Z'' -2.69 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Xeris Biopharma Holdings, Inc. (XERS) is a Chicago-based, commercial-stage biopharmaceutical firm specializing in endocrine and neurological therapies. The company’s primary portfolio includes Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for Cushing’s syndrome. Its late-stage pipeline is currently focused on XP-8121, a weekly subcutaneous treatment for hypothyroidism currently in Phase 3 clinical trials.
The company utilizes its proprietary XeriSol and XeriLend formulation platforms to develop liquid-stable, high-concentration injectables. This business model focuses on reformulating existing drugs to improve delivery and patient adherence, a common strategy in the specialty pharmaceutical sector to extend patent life and reduce developmental risk compared to new molecular entities.
For a deeper look into the companys valuation metrics and financial health, consider reviewing the data available on ValueRay.
- Recorlev market share expansion drives revenue growth in Cushing’s syndrome segment
- Gvoke prescription volume and retail pharmacy penetration impact quarterly earnings
- XP-8121 Phase 3 clinical trial results dictate long-term valuation prospects
- Operating expenses and path to sustained profitability influence investor sentiment
- Keveyis pricing stability and patient retention affect core cash flow generation
| Net Income: 12.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 20.74 > 1.0 |
| NWC/Revenue: 42.27% < 20% (prev 30.74%; Δ 11.53% < -1%) |
| CFO/TA 0.12 > 3% & CFO 48.5m > Net Income 12.0m |
| Net Debt (153.1m) to EBITDA (44.9m): 3.41 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (177.6m) vs 12m ago 16.52% < -2% |
| Gross Margin: 81.59% > 18% (prev 80.99%; Δ 0.60% > 0.5%) |
| Asset Turnover: 89.01% > 50% (prev 70.55%; Δ 18.46% > 0%) |
| Interest Coverage Ratio: 1.13 > 6 (EBIT TTM 32.3m / Interest Expense TTM 28.7m) |
| A: 0.34 (Total Current Assets 251.7m - Total Current Liabilities 118.6m) / Total Assets 392.0m |
| B: -1.71 (Retained Earnings -669.1m / Total Assets 392.0m) |
| C: 0.09 (EBIT TTM 32.3m / Avg Total Assets 353.7m) |
| D: 0.03 (Book Value of Equity 13.0m / Total Liabilities 379.0m) |
| Altman-Z'' = -2.69 = D |
| DSRI: 0.86 (Receivables 56.3m/46.3m, Revenue 314.9m/222.6m) |
| GMI: 0.99 (GM 80.99% / 81.59%) |
| AQI: 0.73 (AQ_t 0.29 / AQ_t-1 0.39) |
| SGI: 1.41 (Revenue 314.9m / 222.6m) |
| TATA: -0.09 (NI 12.0m - CFO 48.5m) / TA 392.0m) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of June 08, 2026, the stock is trading at USD 6.18 with a total of 1,007,903 shares traded.
Over the past week, the price has changed by +0.32%,
over one month by -6.79%,
over three months by +10.36% and
over the past year by +37.95%.
Xeris Pharmaceuticals has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy XERS.
- StrongBuy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.3 | 82.7% |
P/E Trailing = 88.0
P/E Forward = 76.9231
P/S = 3.3777
P/B = 81.7366
Revenue TTM = 314.9m USD
EBIT TTM = 32.3m USD
EBITDA TTM = 44.9m USD
Long Term Debt = 221.2m USD (from longTermDebt, last quarter)
Short Term Debt = 6.27m USD (from shortTermDebt, last quarter)
Debt = 264.8m USD (corrected: LT Debt 221.2m + ST Debt 6.27m) + Leases 37.3m
Net Debt = 153.1m USD (calculated: Debt 264.8m - CCE 111.8m)
Enterprise Value = 1.22b USD (1.06b + Debt 264.8m - CCE 111.8m)
Interest Coverage Ratio = 1.13 (Ebit TTM 32.3m / Interest Expense TTM 28.7m)
EV/FCF = 25.76x (Enterprise Value 1.22b / FCF TTM 47.2m)
FCF Yield = 3.88% (FCF TTM 47.2m / Enterprise Value 1.22b)
FCF Margin = 15.00% (FCF TTM 47.2m / Revenue TTM 314.9m)
Net Margin = 3.81% (Net Income TTM 12.0m / Revenue TTM 314.9m)
Gross Margin = 81.59% ((Revenue TTM 314.9m - Cost of Revenue TTM 58.0m) / Revenue TTM)
Gross Margin QoQ = 84.02% (prev 77.77%)
Tobins Q-Ratio = 3.10 (Enterprise Value 1.22b / Total Assets 392.0m)
Interest Expense / Debt = 10.82% (Interest Expense 28.7m / Debt 264.8m)
Taxrate = 0.0% (0.0 / 12.0m)
NOPAT = 32.3m (EBIT 32.3m * (1 - 0.00%))
Current Ratio = 2.12 (Total Current Assets 251.7m / Total Current Liabilities 118.6m)
Debt / Equity = 20.35 (Debt 264.8m / totalStockholderEquity, last quarter 13.0m)
Debt / EBITDA = 3.41 (Net Debt 153.1m / EBITDA 44.9m)
Debt / FCF = 3.24 (Net Debt 153.1m / FCF TTM 47.2m)
Total Stockholder Equity = 1.63m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.39% (Net Income 12.0m / Total Assets 392.0m)
RoE = 735.0% (Net Income TTM 12.0m / Total Stockholder Equity 1.63m)
RoCE = 14.50% (EBIT 32.3m / Capital Employed (Equity 1.63m + L.T.Debt 221.2m))
RoIC = 12.24% (NOPAT 32.3m / Invested Capital 263.9m)
WACC = 10.17% (E(1.06b)/V(1.33b) * Re(10.01%) + D(264.8m)/V(1.33b) * Rd(10.82%) * (1-Tc(0.0)))
Discount Rate = 10.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 11.83%
[DCF] Terminal Value 69.32% ; FCFF base≈47.2m ; Y1≈47.4m ; Y5≈50.2m
[DCF] Fair Price = 2.57 (EV 596.5m - Net Debt 153.1m = Equity 443.4m / Shares 172.6m; r=10.17% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.81 | # QB: 0
Revenue Correlation: 99.38 | Revenue CAGR: 34.36% | SUE: 1.25 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=-14.66% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.14 | Chg30d=+0.14% | Revisions=+14% | GrowthEPS=+0.0% | GrowthRev=+32.2%
EPS next Year (2027-12-31): EPS=0.40 | Chg30d=+6.61% | Revisions=+0% | GrowthEPS=+177.2% | GrowthRev=+22.7%
[Analyst] Revisions Ratio: +20%